Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells

Pancreatic ductal adenocarcinoma (PDAC) is a fatal disease and one of the cancer entities with the lowest life expectancy. Beside surgical therapy, no effective therapeutic options are available yet. Here, we show that 4-phenylbutyrate (4-PB), a known and well-tolerable inhibitor of histone deacetyl...

Descripción completa

Detalles Bibliográficos
Autores principales: Ammerpohl, O, Trauzold, A, Schniewind, B, Griep, U, Pilarsky, C, Grutzmann, R, Saeger, H-D, Janssen, O, Sipos, B, Kloppel, G, Kalthoff, H
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360208/
https://www.ncbi.nlm.nih.gov/pubmed/17164759
http://dx.doi.org/10.1038/sj.bjc.6603511

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360208/
https://www.ncbi.nlm.nih.gov/pubmed/17164759
http://dx.doi.org/10.1038/sj.bjc.6603511

Ejemplares similares